GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (NAS:MXCT) » Definitions » Debt-to-Revenue

MaxCyte (MaxCyte) Debt-to-Revenue : 0.41 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is MaxCyte Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

MaxCyte's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.83 Mil. MaxCyte's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $17.82 Mil. MaxCyte's annualized Revenue for the quarter that ended in Mar. 2024 was $45.37 Mil. MaxCyte's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.41.


MaxCyte Debt-to-Revenue Historical Data

The historical data trend for MaxCyte's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte Debt-to-Revenue Chart

MaxCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.27 0.17 0.36 0.45

MaxCyte Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.45 0.50 0.30 0.41

Competitive Comparison of MaxCyte's Debt-to-Revenue

For the Medical Devices subindustry, MaxCyte's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MaxCyte's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where MaxCyte's Debt-to-Revenue falls into.



MaxCyte Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

MaxCyte's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.774 + 17.969) / 41.288
=0.45

MaxCyte's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.825 + 17.815) / 45.368
=0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


MaxCyte Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of MaxCyte's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


MaxCyte (MaxCyte) Business Description

Traded in Other Exchanges
Address
9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Executives
John Joseph Johnston director C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Douglas Doerfler director, officer: President and CEO C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Thomas M. Ross officer: EVP, Global Sales C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Richard Douglas director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Douglas J Swirsky officer: Chief Financial Officer C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Patrick J Balthrop director C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Casdin Partners Master Fund, L.p. 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Cenk Sumen officer: Chief Scientific Officer C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Amanda Louise Murphy officer: Chief Financial Officer C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Maher Masoud officer: EVP and General Counsel C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Ron Holtz officer: SVP and CAO C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Yasir B. Al-wakeel director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Art Mandell director C/O MAXCYTE, INC., C/O 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
William W Brooke director 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Thompson J Stark Phd director